Corticosteroids in Transplantation

Corticosteroids (glucocorticoids such as prednisone, prednisolone, and methylprednisolone) are among the oldest and most broadly acting immunosuppressants in transplantation. They are used at high doses around the time of transplant and to treat acute rejection, and at lower doses for long-term maintenance, but their well-known metabolic and other adverse effects have driven extensive study of steroid-minimization and withdrawal strategies.

Definition

Corticosteroids in transplantation are synthetic glucocorticoids used as immunosuppressants that bind the intracellular glucocorticoid receptor to broadly suppress inflammatory and immune gene expression, reducing cytokine production and lymphocyte function.

Scope

This topic covers the role of glucocorticoids in transplant immunosuppression: their broad anti-inflammatory and immunomodulatory mechanism, their use in induction, maintenance, and the treatment of acute rejection, and the trade-off between their efficacy and their adverse effects that underlies steroid-sparing approaches. It is reference material on the drug class, not prescribing or tapering guidance.

Core questions

• How do glucocorticoids produce broad immunosuppression at the molecular level?
• What are the distinct roles of corticosteroids in induction, maintenance, and rejection treatment?
• Why are steroid-minimization and withdrawal strategies pursued?
• What is the trade-off between rejection risk and adverse effects when steroids are reduced?

Key concepts

• Glucocorticoid receptor and gene transcription
• Broad cytokine and inflammatory suppression
• Pulse steroids for acute rejection
• Maintenance low-dose steroids
• Steroid avoidance and withdrawal
• Metabolic and cardiovascular adverse effects

Mechanisms

Glucocorticoids diffuse into cells and bind the cytoplasmic glucocorticoid receptor; the activated complex enters the nucleus and modulates transcription of many genes, both inducing anti-inflammatory proteins and repressing pro-inflammatory transcription factors such as NF-kB and AP-1. The result is broad suppression of cytokine production (including interleukins and tumour necrosis factor), reduced antigen presentation, redistribution and impaired function of lymphocytes, and dampening of the inflammatory response. High pulse doses can abort an acute cellular rejection episode, while low maintenance doses contribute background suppression. The same wide-ranging genomic effects account for the metabolic, bone, and cardiovascular adverse effects associated with prolonged use.

Clinical relevance

Corticosteroids remain a component of many regimens and a first-line treatment for acute cellular rejection, but their long-term adverse effects contribute to cardiovascular and metabolic morbidity after transplantation, motivating steroid-sparing strategies. This entry explains the pharmacology and the efficacy-versus-toxicity trade-off for reference and does not provide dosing, tapering, or treatment instructions.

History

Corticosteroids, combined with azathioprine, formed the standard immunosuppressive regimen in the earliest decades of organ transplantation and have remained in use through successive eras. As newer agents reduced reliance on steroids for baseline suppression and the long-term harms of chronic glucocorticoid exposure became clear, steroid-avoidance and steroid-withdrawal protocols were studied extensively, with meta-analyses weighing the increase in rejection against reductions in cardiovascular and metabolic risk.

Debates

Should corticosteroids be withdrawn or avoided in maintenance regimens?

Steroid avoidance and withdrawal reduce metabolic and cardiovascular harms but, in pooled analyses, increase the risk of acute rejection; whether the net balance favours steroid-sparing depends on recipient risk and the rest of the regimen.

Seminal works

• halloran-2004
• knight-2010

Frequently asked questions

Why are corticosteroids used at different doses in transplantation?

High pulse doses are used briefly to treat acute rejection and around the time of transplant, while much lower doses may be continued for maintenance; the level reflects the balance between suppression and adverse effects.

Why are steroid-sparing strategies studied?

Long-term glucocorticoid exposure contributes to metabolic, bone, and cardiovascular harm, so avoiding or withdrawing steroids can reduce these effects - though pooled evidence shows it tends to raise the risk of acute rejection.